Article Text

Download PDFPDF
EP1121 The clinical potential of FOXL2 c.402C>G mutation detection in circulating tumour DNA of patients with granulosa cell tumours
  1. JW Groeneweg1,
  2. JF Roze1,
  3. GM Monroe1,
  4. ST Paijens2,
  5. HW Nijman2,
  6. HS van Meurs3,
  7. LRCW. van Lonkhuijzen3,
  8. JMJ Piek4,
  9. CAR Lok5,
  10. GN Jonges6 and
  11. RP Zweemer1
  1. 1Gynaecological Oncology | UMC Utrecht Cancer Center, University Medical Center Utrecht, Utrecht
  2. 2Obstetrics and Gynaecology, University Medical Center Groningen, Groningen
  3. 3Gynaecological Oncology, Amsterdam UMC, Location AMC, Amsterdam
  4. 4Obstetrics and Gynaecology, Catharina Hospital, Eindhoven
  5. 5Gynaecological Oncology, Antoni van Leeuwenhoek Hospital - The Netherlands Cancer Institute, Amsterdam
  6. 6Pathology, University Medical Center Utrecht, Utrecht, The Netherlands


Introduction/Background Adult granulosa cell tumours (aGCT) are rare ovarian malignancies, molecularly characterized by a single somatic c.402C>G mutation in FOXL2. Recurrent disease after initial surgical treatment occurs in 30–50% of patients. Serum markers are used for diagnosis and follow-up, but are not always accurate for GCT monitoring. The use of circulating tumour DNA (ctDNA) to monitor disease has been suggested in many cancer types. We aimed to assess the presence of FOXL2 mutant ctDNA in aGCT patients and perform an initial evaluation of its potential as a marker for disease activity.

Methodology In a national, multicenter GCT study, plasma samples (n=27) were prospectively collected from 7 patients with primary (n=1) or recurrent (n=6) aGCT harbouring the FOXL2 c.402C>G mutation. Circulating cell-free DNA was extracted and assessed for the FOXL2 mutation using droplet digital PCR. Identification of FOXL2 mutation positive ctDNA, defined as ≥ 3 mutant droplets, was correlated with clinical parameters.

Results The FOXL2 c.402C>G mutation was found in the plasma of 5 out of 7 aGCT patients (71%), with mutant ctDNA fractions ranging between 0.4% and 47.8%. The tumour load in two patients without FOXL2 mutant ctDNA was limited, while all aGCT patients with FOXL2 mutant ctDNA had multifocal recurrent disease. In all ctDNA positive patients, increasing FOXL2 mutant ctDNA levels were associated with disease progression or relapse defined by a rise in serum markers and/or CT scan findings. In 3 out of 4 ctDNA positive patients with plasma taken before and after treatment, the observed clinical response to therapy was accompanied by a marked decrease in FOXL2 mutant ctDNA fractions.

Conclusion FOXL2 c.402C>G mutant ctDNA can be detected in patients with aGCT. Our results suggest that this test may have clinical value in disease monitoring, particularly when standard biomarkers inaccurately reflect tumour burden. Further research in a larger cohort is currently ongoing.

Disclosure Nothing to disclose

Abstract EP1121 Figure 1

FOXL2 ctDNA of recurrent aGCT patient, before (A) and after (B) complete cytoreductive surgery

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.